Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

2017 ASCO Annual Meeting

Low-value practices in oncology contributing to financial toxicity

Dr Bishal Gyawali - Nagoya University, Nagoya, Japan

Low-value practices in oncology contributing to financial toxicity ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )

The past and future of breast cancer treatment—from the papyrus to...

Dr Felipe Ades - Hospital Israelita Albert Einstein, Morumbi, São Paulo

The past and future of breast cancer treatment—from the papyrus to individualised treatment approaches ( Dr Felipe Ades - Hospital Israelita Albert Einstein, Morumbi, São Paulo )

(4/6) ASCO 2017: Expert discussion on the latest in prostate cancer

Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James

(4/6) ASCO 2017: Expert discussion on the latest in prostate cancer ( Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James )

(5/6) ASCO 2017: ASCO highlights in prostate cancer

Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James

(5/6) ASCO 2017: ASCO highlights in prostate cancer ( Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James )

(6/6) ASCO 2017: Round up of expert discussion on the latest in prostate cancer

Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James

(6/6) ASCO 2017: Round up of expert discussion on the latest in prostate cancer ( Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James )

(3/6) ASCO 2017: STAMPEDE data

Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James

(3/6) ASCO 2017: STAMPEDE data ( Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James )

(2/6) ASCO 2017: LATITUDE data

Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James

(2/6) ASCO 2017: LATITUDE data ( Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James )

(1/6) ASCO 2017: Introduction to Expert discussion on the latest in prostate...

Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James

(1/6) ASCO 2017: Introduction to Expert discussion on the latest in prostate cancer ( Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James )

Clinical potential of trastuzumab biosimilar CTP6

Prof Francisco Esteva - NYU Langone Medical Center, New York, USA

Clinical potential of trastuzumab biosimilar CTP6 ( Prof Francisco Esteva - NYU Langone Medical Center, New York, USA )

ASCO 2017: Round up

Dr Bishal Gyawali - Nagoya University, Nagoya, Japan

ASCO 2017: Round up ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )

Updates in melanoma: Treating BRAF and brain metastases

Prof Georgina Long - University of Sydney, Sydney, Australia

Updates in melanoma: Treating BRAF and brain metastases ( Prof Georgina Long - University of Sydney, Sydney, Australia )

Bendamustine for indolent lymphoma reduces relapse after 10 years

Dr Mathias Rummel - University of Giessen, Giessen, Germany

Bendamustine for indolent lymphoma reduces relapse after 10 years ( Dr Mathias Rummel - University of Giessen, Giessen, Germany )

ShortHER trastuzumab treatment of HER2 breast cancer: 9 weeks v 1 year

Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy

ShortHER trastuzumab treatment of HER2 breast cancer: 9 weeks v 1 year ( Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy )

T-VEC and checkpoint therapy for melanoma

Prof Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA

T-VEC and checkpoint therapy for melanoma ( Prof Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA )

Prevalence of homologous recombination deficiency among 53,000 tumour samples

Dr Arielle Heeke - Georgetown Lombardi Comprehensive Cancer Center, Washington...

Prevalence of homologous recombination deficiency among 53,000 tumour samples ( Dr Arielle Heeke - Georgetown Lombardi Comprehensive Cancer Center, Washington, USA )

Natural plant based balm antidote to severe nail toxicity during chemotherapy

Dr Robert Thomas - Cambridge University Hospitals, Cambridge, UK

Natural plant based balm antidote to severe nail toxicity during chemotherapy ( Dr Robert Thomas - Cambridge University Hospitals, Cambridge, UK )

Dacomitinib for EGFR positive lung cancer

Dr Tony Mok, The Chinese University of Hong Kong, Shatin, China

Dacomitinib for EGFR positive lung cancer ( Dr Tony Mok, The Chinese University of Hong Kong, Shatin, China )

New ALK inhibitor alectinib halts lung cancer growth more than a year longer...

Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA

New ALK inhibitor alectinib halts lung cancer growth more than a year longer than crizotinib, with fewer severe side effects ( Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA )

ASCO 2017: Expert discussion on the latest in prostate cancer

Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James

ASCO 2017: Expert discussion on the latest in prostate cancer ( Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James )

ASCO 2017: Following the practice changing results from STAMPEDE

Dr Neal Shore and Prof Nicholas James

ASCO 2017: Following the practice changing results from STAMPEDE ( Dr Neal Shore and Prof Nicholas James )

Treating advanced melanoma with ipilimumab and HF10

Prof Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA

Treating advanced melanoma with ipilimumab and HF10 ( Prof Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA )

Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers

Dr Bob Li - Memorial Sloan Kettering Cancer Center, New York, USA

Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers ( Dr Bob Li - Memorial Sloan Kettering Cancer Center, New York, USA )

Immunotherapy may slow the growth of malignant pleural mesothelioma

Dr Arnaud Scherpereel - University Hospital of Lille, Lille, France

Immunotherapy may slow the growth of malignant pleural mesothelioma ( Dr Arnaud Scherpereel - University Hospital of Lille, Lille, France )

Immunotherapy for mesothelioma could be on the horizon

Dr Arnaud Scherpereel - University Hospital of Lille, Lille, France

Immunotherapy for mesothelioma could be on the horizon ( Dr Arnaud Scherpereel - University Hospital of Lille, Lille, France )

CAR T-cell therapy can be used to send multiple myeloma into lasting remission

Dr Wanhong Zhao - Xi’an Jiaotong University Hospital, China

CAR T-cell therapy can be used to send multiple myeloma into lasting remission ( Dr Wanhong Zhao - Xi’an Jiaotong University Hospital, China )

Alectinib eclipses crizotinib for ALK positive lung cancer

Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA

Alectinib eclipses crizotinib for ALK positive lung cancer ( Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA )

Adding a second HER2 targeted medicine may lower chance of invasive breast...

Dr Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany

Adding a second HER2 targeted medicine may lower chance of invasive breast cancer ( Dr Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany )

Targeted sequencing in endocrine refractory breast cancer

Dr John Bartlett - Ontario Institute for Cancer Research, Toronto, Canada

$Targeted sequencing in endocrine refractory breast cancer ( Dr John Bartlett - Ontario Institute for Cancer Research, Toronto, Canada )$

Results from the APHINITY trial of two HER2 targeted agents with chemo

Prof Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany

Results from the APHINITY trial of two HER2 targeted agents with chemo ( Prof Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany )

Treating BRCA breast cancer with PARP inhibition

Dr Mika Sovak - AstraZeneca, Cambridge, UK

Treating BRCA breast cancer with PARP inhibition ( Dr Mika Sovak - AstraZeneca, Cambridge, UK )

Relieving spinal cord compression symptoms with a single radiation treatment

Prof Peter Hoskin - Mount Vernon Cancer Centre, Northwood, United Kingdom

Relieving spinal cord compression symptoms with a single radiation treatment ( Prof Peter Hoskin - Mount Vernon Cancer Centre, Northwood, United Kingdom )

Implementing new health initiatives in low-resource environments

Prof Sana Al Sakhun - Jordanian Oncology Society, Jordan

Implementing new health initiatives in low-resource environments ( Prof Sana Al Sakhun - Jordanian Oncology Society, Jordan )

Halving duration of ADT for high risk prostate cancer patients

Prof Abdenour Nabid - Sherbrooke University Hospital Centre, Sherbrooke, Canada

Halving duration of ADT for high risk prostate cancer patients ( Prof Abdenour Nabid - Sherbrooke University Hospital Centre, Sherbrooke, Canada )

Findings of a phase I/II study of nivolumab in patients with virus-associated...

Dr Antoine Hollebecque - Institut Gustave Roussy, Paris, France

Findings of a phase I/II study of nivolumab in patients with virus-associated tumours ( Dr Antoine Hollebecque - Institut Gustave Roussy, Paris, France )

New personalised therapies for lung cancer

Dr Luis Raez - Memorial Cancer Institute, Hollywood, Florida, USA

New personalised therapies for lung cancer ( Dr Luis Raez - Memorial Cancer Institute, Hollywood, Florida, USA )

Nivolumab and ipilimumab for metastatic sarcoma

Dr Sandra D'Angelo - Memorial Sloan Kettering Cancer Center, New York, USA

Nivolumab and ipilimumab for metastatic sarcoma ( Dr Sandra D'Angelo - Memorial Sloan Kettering Cancer Center, New York, USA )

Selumetinib in children with recurrent or refractory low-grade glioma

Dr Jason Fangusaro - Ann & Robert H. Lurie Children's Hospital of Chicago...

$Selumetinib in children with recurrent or refractory low-grade glioma ( Dr Jason Fangusaro - Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, USA )$

Dose escalation results of ceritinib and nivolumab for ALK NSCLC

Dr Enriqueta Felip - Vall d’Hebron University Hospital, Barcelona, Spain

Dose escalation results of ceritinib and nivolumab for ALK NSCLC ( Dr Enriqueta Felip - Vall d’Hebron University Hospital, Barcelona, Spain )

Phase III results of olaparib for BRCA breast cancer

Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA

Phase III results of olaparib for BRCA breast cancer ( Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA )

Global health initiative oncology

Prof Ophira Ginsburg - NYU Langone Medical Center, New York, USA

Global health initiative oncology ( Prof Ophira Ginsburg - NYU Langone Medical Center, New York, USA )

Self-reporting symptoms online improves patient care, chemotherapy duration and...

Prof Ethan Basch - Lineberger Comprehensive Cancer Centre of the University of...

Self-reporting symptoms online improves patient care, chemotherapy duration and survival ( Prof Ethan Basch - Lineberger Comprehensive Cancer Centre of the University of North Carolina, USA )

Tivantinib as second line therapy for high-MET HCC

Prof Lorenza Rimassa - Humanitas Cancer Center, Milan, Italy

Tivantinib as second line therapy for high-MET HCC ( Prof Lorenza Rimassa - Humanitas Cancer Center, Milan, Italy )

9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy

Prof Valentina Guarneri - Università degli Studi di Padova, Padua, Italy

9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy ( Prof Valentina Guarneri - Università degli Studi di Padova, Padua, Italy )

Expert prostate discussion: Clinical diagnostics, genomics, systemic and...

Dr Chris Parker and Prof Charles Ryan

Expert prostate discussion: Clinical diagnostics, genomics, systemic and radiological treatment ( Dr Chris Parker and Prof Charles Ryan )

Global study sets new risk-based standard to personalise chemotherapy for colon...

Dr Axel Grothey - Mayo Clinic Cancer Centre, Rochester, USA

Global study sets new risk-based standard to personalise chemotherapy for colon cancer after surgery ( Dr Axel Grothey - Mayo Clinic Cancer Centre, Rochester, USA )

Olaparib slows growth of BRCA-related metastatic breast cancer

Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA

Olaparib slows growth of BRCA-related metastatic breast cancer ( Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA )

Web-based system for self-reporting symptoms may help patients live longer

Prof Ethan Basch - Lineberger Comprehensive Cancer Centre of the University of...

Web-based system for self-reporting symptoms may help patients live longer ( Prof Ethan Basch - Lineberger Comprehensive Cancer Centre of the University of North Carolina, USA )

3 or 6 months adjuvant oxaliplatin for colorectal cancer

Dr Tim Iveson - University Hospital Southampton, Salisbury, UK

3 or 6 months adjuvant oxaliplatin for colorectal cancer ( Dr Tim Iveson - University Hospital Southampton, Salisbury, UK )

No link between pregnancy and breast cancer relapse

Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium

No link between pregnancy and breast cancer relapse ( Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium )

Cancer and caring in modern medicine

Prof Siddhartha Mukherjee - Columbia University Medical Center, New York, USA

Cancer and caring in modern medicine ( Prof Siddhartha Mukherjee - Columbia University Medical Center, New York, USA )

Pooled analysis of avelumab for metastatic urothelial carcinoma

Dr Andrea Apolo - National Cancer Institute, Bethesda, USA

Pooled analysis of avelumab for metastatic urothelial carcinoma ( Dr Andrea Apolo - National Cancer Institute, Bethesda, USA )

Cancer and living meaningfully: the CALM intervention

Dr Gary Rodin - Princess Margaret Cancer Centre, Toronto, Canada

Cancer and living meaningfully: the CALM intervention ( Dr Gary Rodin - Princess Margaret Cancer Centre, Toronto, Canada )

'Conquer Fear' of disease recurrence

Dr Jane Beith - University of Sydney, Sydney, Australia

'Conquer Fear' of disease recurrence ( Dr Jane Beith - University of Sydney, Sydney, Australia )

Screening for 508 genes in liquid biopsy to chart cancer evolution

Dr Pedram Razavi - Memorial Sloan Kettering Cancer Centre, New York, USA

Screening for 508 genes in liquid biopsy to chart cancer evolution ( Dr Pedram Razavi - Memorial Sloan Kettering Cancer Centre, New York, USA )

Larotrectinib shows durable efficacy across diverse paediatric and adult cancers

Dr David Hyman - Memorial Sloan Kettering Cancer Centre, New York, USA

Larotrectinib shows durable efficacy across diverse paediatric and adult cancers ( Dr David Hyman - Memorial Sloan Kettering Cancer Centre, New York, USA )

Routine genomic testing is feasible, but only a subset of patients benefit

Dr Olivier Trédan - Centre Léon Bérard, Lyon, France

Routine genomic testing is feasible, but only a subset of patients benefit ( Dr Olivier Trédan - Centre Léon Bérard, Lyon, France )

Molecular profiles and the future of adjuvant therapy

Dr Rodrigo Dienstmann - Vall d’Hebron Institute of Oncology, Barcelona, Spain

Molecular profiles and the future of adjuvant therapy ( Dr Rodrigo Dienstmann - Vall d’Hebron Institute of Oncology, Barcelona, Spain )

Pregnancy after breast cancer no associated with relapse risk

Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium

Pregnancy after breast cancer no associated with relapse risk ( Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium )

Delaying metastatic prostate cancer, improving survival with abiraterone

Prof Karim Fizazi - Institut Gustave Roussy, Paris, France

Delaying metastatic prostate cancer, improving survival with abiraterone ( Prof Karim Fizazi - Institut Gustave Roussy, Paris, France )

STAMPEDE trial: abiraterone for advanced prostate cancer reduces progression...

Prof Nick James - Queen Elizabeth Hospital Birmingham & University of...

STAMPEDE trial: abiraterone for advanced prostate cancer reduces progression/deaths ( Prof Nick James - Queen Elizabeth Hospital Birmingham & University of Birmingham, UK )

Hypogonadism following cisplatin treatment of testicular cancer

Dr Mohammad Issam Abu Zaid - Indiana University School of Medicine...

Hypogonadism following cisplatin treatment of testicular cancer ( Dr Mohammad Issam Abu Zaid - Indiana University School of Medicine, Indianapolis, USA )

Recent childhood cancer survivors face less chronic disease risk than previous...

Dr Todd Gibson - St Jude Children's Research Hospital, Memphis, USA

Recent childhood cancer survivors face less chronic disease risk than previous decades ( Dr Todd Gibson - St Jude Children's Research Hospital, Memphis, USA )

Steady decrease in severe health problems for childhood cancer survivors

Dr Todd M. Gibson - St Jude Children's Research Hospital, Memphis, USA

Steady decrease in severe health problems for childhood cancer survivors ( Dr Todd M. Gibson - St Jude Children's Research Hospital, Memphis, USA )

Low testosterone after testicular cancer could be linked to chronic health...

Dr Mohammad Issam Abu Zaid - Indiana University School of Medicine...

Low testosterone after testicular cancer could be linked to chronic health problems ( Dr Mohammad Issam Abu Zaid - Indiana University School of Medicine, Indianapolis, USA )

Single radiation treatment can sufficiently relieve spinal cord compression...

Prof Peter Hoskin - Mount Vernon Cancer Centre, Northwood, United Kingdom

Single radiation treatment can sufficiently relieve spinal cord compression symptoms ( Prof Peter Hoskin - Mount Vernon Cancer Centre, Northwood, United Kingdom )

Web-based remote therapy program improves quality of life and lowers distress...

Dr Viviane Hess - University Hospital of Basel, Basel, Switzerland

Web-based remote therapy program improves quality of life and lowers distress after diagnosis ( Dr Viviane Hess - University Hospital of Basel, Basel, Switzerland )

Easing distress in patients with cognitive therapy

Dr Gary Rodin - Princess Margaret Cancer Centre, Toronto, Canada

Easing distress in patients with cognitive therapy ( Dr Gary Rodin - Princess Margaret Cancer Centre, Toronto, Canada )

Psychological intervention lowers fear of cancer recurrence

Dr Jane Beith - University of Sydney, Australia

Psychological intervention lowers fear of cancer recurrence ( Dr Jane Beith - University of Sydney, Australia )

More from ecancer